

## GCHP Medi-Cal Clinical Guidelines Arsenic Trioxide (Trisenox™)

PA Criteria	Criteria Details		
Covered Uses (FDA approved indication)	Induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the (15;17) translocation or PML/RAR-alpha gene expression.		
Exclusion Criteria	None.		
Required Medical Information	FDA – approved indication and dosing regimen.		
Age Restriction	4 years of age and older. 4 - 21 years of age, check for CCS eligibility.		
Prescriber Restrictions	Hematologist, Oncologist		
Coverage Duration	Three months.		
Other Criteria / Information	Adapted from DHCS Pharmacy Manual Chemo Drug a May 2024.		
	HCPCS	Description	Dosing, Units
	J9017	Arsenic trioxide 1mg injection (Trisenox)	<u>Induction:</u> 0.15mg/kg daily until bone marrow suppression, maximum of 60 doses. <u>Consolidation:</u> 0.15mg/kg daily for 25 doses over five weeks.

STATUS	DATE REVISED	REVIEW DATE	APPROVED / REVIEWED BY	EFFECTIVE DATE
Created	1/15/2025		Yoonhee Kim, Clinical Programs Pharmacist Lily Yip, Director of Pharmacy Services	N/A
Approved	N/A	2/13/2025	Pharmacy & Therapeutics (P&T) Committee	6/1/2025